Risedronate in children with osteogenesis imperfecta: a randomised, double-blind, placebo-controlled trial
Children with osteogenesis imperfecta are often treated with intravenous bisphosphonates. We aimed to assess the safety and efficacy of risedronate, an orally administered third-generation bisphosphonate, in children with the disease. In this multicentre, randomised, parallel, double-blind, placebo-...
Saved in:
| Published in | The Lancet (British edition) Vol. 382; no. 9902; pp. 1424 - 1432 |
|---|---|
| Main Authors | , , , , , , , , , , , , , , , , , , , , , |
| Format | Journal Article |
| Language | English |
| Published |
Kidlington
Elsevier Ltd
26.10.2013
Elsevier Elsevier Limited |
| Subjects | |
| Online Access | Get full text |
| ISSN | 0140-6736 1474-547X 1474-547X |
| DOI | 10.1016/S0140-6736(13)61091-0 |
Cover
| Abstract | Children with osteogenesis imperfecta are often treated with intravenous bisphosphonates. We aimed to assess the safety and efficacy of risedronate, an orally administered third-generation bisphosphonate, in children with the disease.
In this multicentre, randomised, parallel, double-blind, placebo-controlled trial, children aged 4–15 years with osteogenesis imperfecta and increased fracture risk were randomly assigned by telephone randomisation system in a 2:1 ratio to receive either daily risedronate (2·5 or 5 mg) or placebo for 1 year. Study treatment was masked from patients, investigators, and study centre personnel. Thereafter, all children received risedronate for 2 additional years in an open-label extension. The primary efficacy endpoint was percentage change in lumbar spine areal bone mineral density (BMD) at 1 year. The primary efficacy analysis was done by ANCOVA, with treatment, age group, and pooled centre as fixed effects, and baseline as covariate. Analyses were based on the intention-to-treat population, which included all patients who were randomly assigned and took at least one dose of assigned study treatment. The trial is registered with ClinicalTrials.gov, number NCT00106028.
Of 147 patients, 97 were randomly assigned to the risedronate group and 50 to the placebo group. Three patients from the risedronate group and one from the placebo group did not receive study treatment, leaving 94 and 49 in the intention-to-treat population, respectively. The mean increase in lumbar spine areal BMD after 1 year was 16·3% in the risedronate group and 7·6% in the placebo group (difference 8·7%, 95% CI 5·7–11·7; p<0·0001). After 1 year, clinical fractures had occurred in 29 (31%) of 94 patients in the risedronate group and 24 (49%) of 49 patients in the placebo group (p=0·0446). During years 2 and 3 (open-label phase), clinical fractures were reported in 46 (53%) of 87 patients in the group that had received risedronate since the start of the study, and 32 (65%) of 49 patients in the group that had been given placebo during the first year. Adverse event profiles were otherwise similar between the two groups, including frequencies of reported upper-gastrointestinal and selected musculoskeletal adverse events.
Oral risedronate increased areal BMD and reduced the risk of first and recurrent clinical fractures in children with osteogenesis imperfecta, and the drug was generally well tolerated. Risedronate should be regarded as a treatment option for children with osteogenesis imperfecta.
Alliance for Better Bone Health (Warner Chilcott and Sanofi). |
|---|---|
| AbstractList | Children with osteogenesis imperfecta are often treated with intravenous bisphosphonates. We aimed to assess the safety and efficacy of risedronate, an orally administered third-generation bisphosphonate, in children with the disease.BACKGROUNDChildren with osteogenesis imperfecta are often treated with intravenous bisphosphonates. We aimed to assess the safety and efficacy of risedronate, an orally administered third-generation bisphosphonate, in children with the disease.In this multicentre, randomised, parallel, double-blind, placebo-controlled trial, children aged 4-15 years with osteogenesis imperfecta and increased fracture risk were randomly assigned by telephone randomisation system in a 2:1 ratio to receive either daily risedronate (2·5 or 5 mg) or placebo for 1 year. Study treatment was masked from patients, investigators, and study centre personnel. Thereafter, all children received risedronate for 2 additional years in an open-label extension. The primary efficacy endpoint was percentage change in lumbar spine areal bone mineral density (BMD) at 1 year. The primary efficacy analysis was done by ANCOVA, with treatment, age group, and pooled centre as fixed effects, and baseline as covariate. Analyses were based on the intention-to-treat population, which included all patients who were randomly assigned and took at least one dose of assigned study treatment. The trial is registered with ClinicalTrials.gov, number NCT00106028.METHODSIn this multicentre, randomised, parallel, double-blind, placebo-controlled trial, children aged 4-15 years with osteogenesis imperfecta and increased fracture risk were randomly assigned by telephone randomisation system in a 2:1 ratio to receive either daily risedronate (2·5 or 5 mg) or placebo for 1 year. Study treatment was masked from patients, investigators, and study centre personnel. Thereafter, all children received risedronate for 2 additional years in an open-label extension. The primary efficacy endpoint was percentage change in lumbar spine areal bone mineral density (BMD) at 1 year. The primary efficacy analysis was done by ANCOVA, with treatment, age group, and pooled centre as fixed effects, and baseline as covariate. Analyses were based on the intention-to-treat population, which included all patients who were randomly assigned and took at least one dose of assigned study treatment. The trial is registered with ClinicalTrials.gov, number NCT00106028.Of 147 patients, 97 were randomly assigned to the risedronate group and 50 to the placebo group. Three patients from the risedronate group and one from the placebo group did not receive study treatment, leaving 94 and 49 in the intention-to-treat population, respectively. The mean increase in lumbar spine areal BMD after 1 year was 16·3% in the risedronate group and 7·6% in the placebo group (difference 8·7%, 95% CI 5·7-11·7; p<0·0001). After 1 year, clinical fractures had occurred in 29 (31%) of 94 patients in the risedronate group and 24 (49%) of 49 patients in the placebo group (p=0·0446). During years 2 and 3 (open-label phase), clinical fractures were reported in 46 (53%) of 87 patients in the group that had received risedronate since the start of the study, and 32 (65%) of 49 patients in the group that had been given placebo during the first year. Adverse event profiles were otherwise similar between the two groups, including frequencies of reported upper-gastrointestinal and selected musculoskeletal adverse events.FINDINGSOf 147 patients, 97 were randomly assigned to the risedronate group and 50 to the placebo group. Three patients from the risedronate group and one from the placebo group did not receive study treatment, leaving 94 and 49 in the intention-to-treat population, respectively. The mean increase in lumbar spine areal BMD after 1 year was 16·3% in the risedronate group and 7·6% in the placebo group (difference 8·7%, 95% CI 5·7-11·7; p<0·0001). After 1 year, clinical fractures had occurred in 29 (31%) of 94 patients in the risedronate group and 24 (49%) of 49 patients in the placebo group (p=0·0446). During years 2 and 3 (open-label phase), clinical fractures were reported in 46 (53%) of 87 patients in the group that had received risedronate since the start of the study, and 32 (65%) of 49 patients in the group that had been given placebo during the first year. Adverse event profiles were otherwise similar between the two groups, including frequencies of reported upper-gastrointestinal and selected musculoskeletal adverse events.Oral risedronate increased areal BMD and reduced the risk of first and recurrent clinical fractures in children with osteogenesis imperfecta, and the drug was generally well tolerated. Risedronate should be regarded as a treatment option for children with osteogenesis imperfecta.INTERPRETATIONOral risedronate increased areal BMD and reduced the risk of first and recurrent clinical fractures in children with osteogenesis imperfecta, and the drug was generally well tolerated. Risedronate should be regarded as a treatment option for children with osteogenesis imperfecta.Alliance for Better Bone Health (Warner Chilcott and Sanofi).FUNDINGAlliance for Better Bone Health (Warner Chilcott and Sanofi). Background Children with osteogenesis imperfecta are often treated with intravenous bisphosphonates. We aimed to assess the safety and efficacy of risedronate, an orally administered third-generation bisphosphonate, in children with the disease. Methods In this multicentre, randomised, parallel, double-blind, placebo-controlled trial, children aged 4-15 years with osteogenesis imperfecta and increased fracture risk were randomly assigned by telephone randomisation system in a 2:1 ratio to receive either daily risedronate (2 times 5 or 5 mg) or placebo for 1 year. Study treatment was masked from patients, investigators, and study centre personnel. Thereafter, all children received risedronate for 2 additional years in an open-label extension. The primary efficacy endpoint was percentage change in lumbar spine areal bone mineral density (BMD) at 1 year. The primary efficacy analysis was done by ANCOVA, with treatment, age group, and pooled centre as fixed effects, and baseline as covariate. Analyses were based on the intention-to-treat population, which included all patients who were randomly assigned and took at least one dose of assigned study treatment. The trial is registered with ClinicalTrials.gov, number NCT00106028. Findings Of 147 patients, 97 were randomly assigned to the risedronate group and 50 to the placebo group. Three patients from the risedronate group and one from the placebo group did not receive study treatment, leaving 94 and 49 in the intention-to-treat population, respectively. The mean increase in lumbar spine areal BMD after 1 year was 16 times 3% in the risedronate group and 7 times 6% in the placebo group (difference 8 times 7%, 95% CI 5 times 7-11 times 7; p<0 times 0001). After 1 year, clinical fractures had occurred in 29 (31%) of 94 patients in the risedronate group and 24 (49%) of 49 patients in the placebo group (p=0 times 0446). During years 2 and 3 (open-label phase), clinical fractures were reported in 46 (53%) of 87 patients in the group that had received risedronate since the start of the study, and 32 (65%) of 49 patients in the group that had been given placebo during the first year. Adverse event profiles were otherwise similar between the two groups, including frequencies of reported upper-gastrointestinal and selected musculoskeletal adverse events. Interpretation Oral risedronate increased areal BMD and reduced the risk of first and recurrent clinical fractures in children with osteogenesis imperfecta, and the drug was generally well tolerated. Risedronate should be regarded as a treatment option for children with osteogenesis imperfecta. Funding Alliance for Better Bone Health (Warner Chilcott and Sanofi). BACKGROUND: Children with osteogenesis imperfecta are often treated with intravenous bisphosphonates. We aimed to assess the safety and efficacy of risedronate, an orally administered third-generation bisphosphonate, in children with the disease. METHODS: In this multicentre, randomised, parallel, double-blind, placebo-controlled trial, children aged 4–15 years with osteogenesis imperfecta and increased fracture risk were randomly assigned by telephone randomisation system in a 2:1 ratio to receive either daily risedronate (2·5 or 5 mg) or placebo for 1 year. Study treatment was masked from patients, investigators, and study centre personnel. Thereafter, all children received risedronate for 2 additional years in an open-label extension. The primary efficacy endpoint was percentage change in lumbar spine areal bone mineral density (BMD) at 1 year. The primary efficacy analysis was done by ANCOVA, with treatment, age group, and pooled centre as fixed effects, and baseline as covariate. Analyses were based on the intention-to-treat population, which included all patients who were randomly assigned and took at least one dose of assigned study treatment. The trial is registered with ClinicalTrials.gov, number NCT00106028. FINDINGS: Of 147 patients, 97 were randomly assigned to the risedronate group and 50 to the placebo group. Three patients from the risedronate group and one from the placebo group did not receive study treatment, leaving 94 and 49 in the intention-to-treat population, respectively. The mean increase in lumbar spine areal BMD after 1 year was 16·3% in the risedronate group and 7·6% in the placebo group (difference 8·7%, 95% CI 5·7–11·7; p<0·0001). After 1 year, clinical fractures had occurred in 29 (31%) of 94 patients in the risedronate group and 24 (49%) of 49 patients in the placebo group (p=0·0446). During years 2 and 3 (open-label phase), clinical fractures were reported in 46 (53%) of 87 patients in the group that had received risedronate since the start of the study, and 32 (65%) of 49 patients in the group that had been given placebo during the first year. Adverse event profiles were otherwise similar between the two groups, including frequencies of reported upper-gastrointestinal and selected musculoskeletal adverse events. INTERPRETATION: Oral risedronate increased areal BMD and reduced the risk of first and recurrent clinical fractures in children with osteogenesis imperfecta, and the drug was generally well tolerated. Risedronate should be regarded as a treatment option for children with osteogenesis imperfecta. FUNDING: Alliance for Better Bone Health (Warner Chilcott and Sanofi). Children with osteogenesis imperfecta are often treated with intravenous bisphosphonates. We aimed to assess the safety and efficacy of risedronate, an orally administered third-generation bisphosphonate, in children with the disease. Methods In this multicentre, randomised, parallel, double-blind, placebo-controlled trial, children aged 4-15 years with osteogenesis imperfecta and increased fracture risk were randomly assigned by telephone randomisation system in a 2:1 ratio to receive either daily risedronate (2·5 or 5 mg) or placebo for 1 year. Study treatment was masked from patients, investigators, and study centre personnel. Thereafter, all children received risedronate for 2 additional years in an open-label extension. The primary efficacy endpoint was percentage change in lumbar spine areal bone mineral density (BMD) at 1 year. The primary efficacy analysis was done by ANCOVA, with treatment, age group, and pooled centre as fixed effects, and baseline as covariate. Analyses were based on the intention-to-treat population, which included all patients who were randomly assigned and took at least one dose of assigned study treatment. The trial is registered withClinicalTrials.gov, numberNCT00106028. Findings Of 147 patients, 97 were randomly assigned to the risedronate group and 50 to the placebo group. Three patients from the risedronate group and one from the placebo group did not receive study treatment, leaving 94 and 49 in the intention-to-treat population, respectively. The mean increase in lumbar spine areal BMD after 1 year was 16·3% in the risedronate group and 7·6% in the placebo group (difference 8·7%, 95% CI 5·7-11·7; p<0·0001). After 1 year, clinical fractures had occurred in 29 (31%) of 94 patients in the risedronate group and 24 (49%) of 49 patients in the placebo group (p=0·0446). During years 2 and 3 (open-label phase), clinical fractures were reported in 46 (53%) of 87 patients in the group that had received risedronate since the start of the study, and 32 (65%) of 49 patients in the group that had been given placebo during the first year. Adverse event profiles were otherwise similar between the two groups, including frequencies of reported upper-gastrointestinal and selected musculoskeletal adverse events. Interpretation Oral risedronate increased areal BMD and reduced the risk of first and recurrent clinical fractures in children with osteogenesis imperfecta, and the drug was generally well tolerated. Risedronate should be regarded as a treatment option for children with osteogenesis imperfecta. Funding Alliance for Better Bone Health (Warner Chilcott and Sanofi). Children with osteogenesis imperfecta are often treated with intravenous bisphosphonates. We aimed to assess the safety and efficacy of risedronate, an orally administered third-generation bisphosphonate, in children with the disease. In this multicentre, randomised, parallel, double-blind, placebo-controlled trial, children aged 4-15 years with osteogenesis imperfecta and increased fracture risk were randomly assigned by telephone randomisation system in a 2:1 ratio to receive either daily risedronate (2·5 or 5 mg) or placebo for 1 year. Study treatment was masked from patients, investigators, and study centre personnel. Thereafter, all children received risedronate for 2 additional years in an open-label extension. The primary efficacy endpoint was percentage change in lumbar spine areal bone mineral density (BMD) at 1 year. The primary efficacy analysis was done by ANCOVA, with treatment, age group, and pooled centre as fixed effects, and baseline as covariate. Analyses were based on the intention-to-treat population, which included all patients who were randomly assigned and took at least one dose of assigned study treatment. The trial is registered with ClinicalTrials.gov, number NCT00106028. Of 147 patients, 97 were randomly assigned to the risedronate group and 50 to the placebo group. Three patients from the risedronate group and one from the placebo group did not receive study treatment, leaving 94 and 49 in the intention-to-treat population, respectively. The mean increase in lumbar spine areal BMD after 1 year was 16·3% in the risedronate group and 7·6% in the placebo group (difference 8·7%, 95% CI 5·7-11·7; p<0·0001). After 1 year, clinical fractures had occurred in 29 (31%) of 94 patients in the risedronate group and 24 (49%) of 49 patients in the placebo group (p=0·0446). During years 2 and 3 (open-label phase), clinical fractures were reported in 46 (53%) of 87 patients in the group that had received risedronate since the start of the study, and 32 (65%) of 49 patients in the group that had been given placebo during the first year. Adverse event profiles were otherwise similar between the two groups, including frequencies of reported upper-gastrointestinal and selected musculoskeletal adverse events. Oral risedronate increased areal BMD and reduced the risk of first and recurrent clinical fractures in children with osteogenesis imperfecta, and the drug was generally well tolerated. Risedronate should be regarded as a treatment option for children with osteogenesis imperfecta. Alliance for Better Bone Health (Warner Chilcott and Sanofi). Background: Children with osteogenesis imperfecta are often treated with intravenous bisphosphonates. We aimed to assess the safety and efficacy of risedronate, an orally administered third-generation bisphosphonate, in children with the disease. Methods: In this multicentre, randomised, parallel, double-blind, placebo-controlled trial, children aged 4-15 years with osteogenesis imperfecta and increased fracture risk were randomly assigned by telephone randomisation system in a 2:1 ratio to receive either daily risedronate (2.5 or 5 mg) or placebo for 1 year. Study treatment was masked from patients, investigators, and study centre personnel. Thereafter, all children received risedronate for 2 additional years in an open-label extension. The primary efficacy endpoint was percentage change in lumbar spine areal bone mineral density (BMD) at 1 year. The primary efficacy analysis was done by ANCOVA, with treatment, age group, and pooled centre as fixed effects, and baseline as covariate. Analyses were based on the intention-to-treat population, which included all patients who were randomly assigned and took at least one dose of assigned study treatment. The trial is registered with ClinicalTrials.gov, number NCT00106028. Findings: Of 147 patients, 97 were randomly assigned to the risedronate group and 50 to the placebo group. Three patients from the risedronate group and one from the placebo group did not receive study treatment, leaving 94 and 49 in the intention-to-treat population, respectively. The mean increase in lumbar spine areal BMD after 1 year was 16.3% in the risedronate group and 7.6% in the placebo group (difference 8.7%, 95% CI 5.7-11.7; p<0.0001). After 1 year, clinical fractures had occurred in 29 (31%) of 94 patients in the risedronate group and 24 (49%) of 49 patients in the placebo group (p=0.0446). During years 2 and 3 (open-label phase), clinical fractures were reported in 46 (53%) of 87 patients in the group that had received risedronate since the start of the study, and 32 (65%) of 49 patients in the group that had been given placebo during the first year. Adverse event profiles were otherwise similar between the two groups, including frequencies of reported upper-gastrointestinal and selected musculoskeletal adverse events. Interpretation: Oral risedronate increased areal BMD and reduced the risk of first and recurrent clinical fractures in children with osteogenesis imperfecta, and the drug was generally well tolerated. Risedronate should be regarded as a treatment option for children with osteogenesis imperfecta. Funding Alliance for Better Bone Health (Warner Chilcott and Sanofi). Summary Background Children with osteogenesis imperfecta are often treated with intravenous bisphosphonates. We aimed to assess the safety and efficacy of risedronate, an orally administered third-generation bisphosphonate, in children with the disease. Methods In this multicentre, randomised, parallel, double-blind, placebo-controlled trial, children aged 4–15 years with osteogenesis imperfecta and increased fracture risk were randomly assigned by telephone randomisation system in a 2:1 ratio to receive either daily risedronate (2·5 or 5 mg) or placebo for 1 year. Study treatment was masked from patients, investigators, and study centre personnel. Thereafter, all children received risedronate for 2 additional years in an open-label extension. The primary efficacy endpoint was percentage change in lumbar spine areal bone mineral density (BMD) at 1 year. The primary efficacy analysis was done by ANCOVA, with treatment, age group, and pooled centre as fixed effects, and baseline as covariate. Analyses were based on the intention-to-treat population, which included all patients who were randomly assigned and took at least one dose of assigned study treatment. The trial is registered with ClinicalTrials.gov , number NCT00106028. Findings Of 147 patients, 97 were randomly assigned to the risedronate group and 50 to the placebo group. Three patients from the risedronate group and one from the placebo group did not receive study treatment, leaving 94 and 49 in the intention-to-treat population, respectively. The mean increase in lumbar spine areal BMD after 1 year was 16·3% in the risedronate group and 7·6% in the placebo group (difference 8·7%, 95% CI 5·7–11·7; p<0·0001). After 1 year, clinical fractures had occurred in 29 (31%) of 94 patients in the risedronate group and 24 (49%) of 49 patients in the placebo group (p=0·0446). During years 2 and 3 (open-label phase), clinical fractures were reported in 46 (53%) of 87 patients in the group that had received risedronate since the start of the study, and 32 (65%) of 49 patients in the group that had been given placebo during the first year. Adverse event profiles were otherwise similar between the two groups, including frequencies of reported upper-gastrointestinal and selected musculoskeletal adverse events. Interpretation Oral risedronate increased areal BMD and reduced the risk of first and recurrent clinical fractures in children with osteogenesis imperfecta, and the drug was generally well tolerated. Risedronate should be regarded as a treatment option for children with osteogenesis imperfecta. Funding Alliance for Better Bone Health (Warner Chilcott and Sanofi). |
| Author | Lorenc, Roman Pavlov, Helene Ahmed, S Faisal Plotkin, Horacio Adami, Silvano Burren, Christine P Bishop, Nick Hosszú, Eva Antón, Jordi Mäkitie, Outi Sillence, David O Hangartner, Thomas Semler, Oliver Paredes, Ana Schoenau, Eckhard Arundel, Paul Lane, Joseph M Reyes, Maria Loreto Devogelaer, Jean-Pierre Munns, Craig F Raggio, Cathleen L Steiner, Robert D |
| Author_xml | – sequence: 1 givenname: Nick surname: Bishop fullname: Bishop, Nick email: n.j.bishop@sheffield.ac.uk organization: Academic Unit of Child Health, Department of Human Metabolism, University of Sheffield, Sheffield Children's Hospital, Sheffield, UK – sequence: 2 givenname: Silvano surname: Adami fullname: Adami, Silvano organization: Rheumatologic Rehabilitation Unit, University of Verona, Verona, Italy – sequence: 3 givenname: S Faisal surname: Ahmed fullname: Ahmed, S Faisal organization: Royal Hospital for Sick Children, University of Glasgow, Glasgow, UK – sequence: 4 givenname: Jordi surname: Antón fullname: Antón, Jordi organization: Paediatric Rheumatology Unit, Paediatrics Department, Hospital Sant Joan de Déu, Universitat de Barcelona, Barcelona, Spain – sequence: 5 givenname: Paul surname: Arundel fullname: Arundel, Paul organization: Academic Unit of Child Health, Department of Human Metabolism, University of Sheffield, Sheffield Children's Hospital, Sheffield, UK – sequence: 6 givenname: Christine P surname: Burren fullname: Burren, Christine P organization: Department of Paediatric Endocrinology and Diabetes, Bristol Royal Hospital for Children, University Hospitals Bristol NHS Foundation Trust, Bristol, UK – sequence: 7 givenname: Jean-Pierre surname: Devogelaer fullname: Devogelaer, Jean-Pierre organization: Université Catholique de Louvain, Saint-Luc University Hospital, Brussels, Belgium – sequence: 8 givenname: Thomas surname: Hangartner fullname: Hangartner, Thomas organization: Biomedical Imaging Laboratory, Wright State University, Dayton, OH, USA – sequence: 9 givenname: Eva surname: Hosszú fullname: Hosszú, Eva organization: Endocrine Ward, Second Department of Paediatrics, Semmelweis University, Budapest, Hungary – sequence: 10 givenname: Joseph M surname: Lane fullname: Lane, Joseph M organization: Department of Orthopedics and Trauma, Hospital for Special Surgery, New York, NY, USA – sequence: 11 givenname: Roman surname: Lorenc fullname: Lorenc, Roman organization: Department of Biochemistry, Radioimmunology, and Experimental Medicine, Children's Memorial Health Institute, Warsaw, Poland – sequence: 12 givenname: Outi surname: Mäkitie fullname: Mäkitie, Outi organization: Paediatric Endocrinology and Metabolic Bone Diseases, Helsinki University Central Hospital and University of Helsinki, Helsinki, Finland – sequence: 13 givenname: Craig F surname: Munns fullname: Munns, Craig F organization: Bone and Mineral Medicine, Sydney Children's Hospital Network, Westmead, NSW, Australia – sequence: 14 givenname: Ana surname: Paredes fullname: Paredes, Ana organization: Herbert Wertheim College of Medicine, Miami Children's Hospital, Miami, FL, USA – sequence: 15 givenname: Helene surname: Pavlov fullname: Pavlov, Helene organization: Department of Radiology and Imaging, Hospital for Special Surgery, New York, NY, USA – sequence: 16 givenname: Horacio surname: Plotkin fullname: Plotkin, Horacio organization: Pediatrics and Orthopedic Surgery, University of Nebraska Medical Center, Children's Hospital, Omaha, NE, USA – sequence: 17 givenname: Cathleen L surname: Raggio fullname: Raggio, Cathleen L organization: Department of Pediatric Orthopedics, Hospital for Special Surgery, New York, NY, USA – sequence: 18 givenname: Maria Loreto surname: Reyes fullname: Reyes, Maria Loreto organization: Pontificia Universidad Católica de Chile, Santiago, Chile – sequence: 19 givenname: Eckhard surname: Schoenau fullname: Schoenau, Eckhard organization: Children's Hospital, University of Cologne, Cologne, Germany – sequence: 20 givenname: Oliver surname: Semler fullname: Semler, Oliver organization: Children's Hospital, University of Cologne, Cologne, Germany – sequence: 21 givenname: David O surname: Sillence fullname: Sillence, David O organization: Connective Tissue Dysplasia Service, Sydney Children's Hospital Network, Westmead, NSW, Australia – sequence: 22 givenname: Robert D surname: Steiner fullname: Steiner, Robert D organization: Marshfield Clinic Research Foundation, Marshfield, WI, USA |
| BackLink | http://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=27816481$$DView record in Pascal Francis https://www.ncbi.nlm.nih.gov/pubmed/23927913$$D View this record in MEDLINE/PubMed http://kipublications.ki.se/Default.aspx?queryparsed=id:127681337$$DView record from Swedish Publication Index |
| BookMark | eNqNku9r1DAch4tM3G36J6iFIUywmt9pFBUZ_oKB4Bz4LqTpt1tuveZMWsf-e9PrbYMDuXvVNDzfT9JPn4Nsr_MdZNlTjF5jhMWbM4QZKoSk4hjTlwIjhQv0IJthJlnBmfy9l83ukP3sIMY5QogJxB9l-4QqIhWms2z-00Wog-9MD7nrcnvp2jpAl1-7_jL3sQd_AR1EF3O3WEJowPbmbW7yYLraL8bhV3nth6qFompdl96WrbFQ-cL6rg--baHO--BM-zh72Jg2wpP18zA7__L518m34vTH1-8nn04LK4noCyythIZIomhtDcFUKmoIYuO64qZqqpJXNVOYcMJkJawSFXArKFVgFBX0MCum3HgNy6HSy-AWJtxob5xeb12lFWhOpFAq8ccTvwz-zwCx1-mzLLSt6cAPUWMhS85LgdB2lAuEseKMb0eZKGmikdoFZRxJpsgOKEe4JALJhB5toHM_hC41nyjGlJRKlol6tqaGagH1XVm3hiTgxRow0Zq2Sf_dunjPyRILVuLEvZs4G3yMARptXW96N0pgXKsx0qO3euWtHqXUmOqVt3oslm9M3x6wbe75NNcYr81FSDc7PyMIc4QwRVyOxMeJgKTcXwdBR-ugs1C7kFzWtXdbz_iwkWCT6C6VcQU3EO9b1ZFoNIWMGZiuEsaA9_8P2OEC_wC5xTLi |
| CODEN | LANCAO |
| CitedBy_id | crossref_primary_10_1002_jbmr_3922 crossref_primary_10_1002_jbmr_2835 crossref_primary_10_1016_j_injury_2015_04_021 crossref_primary_10_1210_jc_2016_3745 crossref_primary_10_1016_j_clindermatol_2015_11_008 crossref_primary_10_23868_gc120565 crossref_primary_10_1097_MED_0000000000000367 crossref_primary_10_1002_jbm4_10592 crossref_primary_10_1080_19396368_2018_1472315 crossref_primary_10_1210_clinem_dgac366 crossref_primary_10_1210_clinem_dgad732 crossref_primary_10_1002_jbmr_2567 crossref_primary_10_1093_cb_cbu027 crossref_primary_10_1097_MJT_0000000000000236 crossref_primary_10_1097_JSM_0000000000000085 crossref_primary_10_1172_jci_insight_149636 crossref_primary_10_1093_mrcr_rxab018 crossref_primary_10_1620_tjem_242_115 crossref_primary_10_1016_j_pcl_2014_08_010 crossref_primary_10_1002_ajmg_a_36545 crossref_primary_10_1177_18632521231217333 crossref_primary_10_15690_pf_v16i1_2001 crossref_primary_10_1186_s13023_019_1004_x crossref_primary_10_1007_s40124_015_0082_z crossref_primary_10_1155_2014_384292 crossref_primary_10_3390_jcm7120479 crossref_primary_10_1016_j_bcp_2023_115584 crossref_primary_10_1136_archdischild_2016_311820 crossref_primary_10_1007_s40265_017_0715_3 crossref_primary_10_1007_s00774_018_0952_x crossref_primary_10_1007_s00112_016_0189_5 crossref_primary_10_1159_000365889 crossref_primary_10_1111_jpc_13768 crossref_primary_10_1016_j_metabol_2017_06_001 crossref_primary_10_1016_j_paed_2015_07_007 crossref_primary_10_1159_000381713 crossref_primary_10_15406_ipcb_2023_09_00299 crossref_primary_10_1007_s00198_016_3515_9 crossref_primary_10_1007_s00774_019_01033_9 crossref_primary_10_1002_jbmr_2975 crossref_primary_10_1186_s40729_018_0148_0 crossref_primary_10_1002_14651858_CD005088_pub4 crossref_primary_10_1016_j_endien_2019_02_001 crossref_primary_10_1007_s10354_015_0361_x crossref_primary_10_1302_2048_0105_25_360181 crossref_primary_10_3389_fendo_2020_00405 crossref_primary_10_1016_S0140_6736_15_00728_X crossref_primary_10_1016_j_bone_2021_115867 crossref_primary_10_1007_s40272_021_00487_7 crossref_primary_10_1517_21678707_2015_1006197 crossref_primary_10_1016_j_bone_2018_05_021 crossref_primary_10_4103_jpbs_JPBS_47_20 crossref_primary_10_1038_nrdp_2017_52 crossref_primary_10_2106_JBJS_N_01085 crossref_primary_10_3389_fphys_2015_00319 crossref_primary_10_1007_s11657_025_01515_6 crossref_primary_10_1007_s00431_018_3127_9 crossref_primary_10_59213_TP_2024_202 crossref_primary_10_1007_s11914_014_0225_0 crossref_primary_10_1007_s00247_015_3537_z crossref_primary_10_1042_BSR20182118 crossref_primary_10_1002_jbmr_3421 crossref_primary_10_1111_os_12611 crossref_primary_10_1097_BPO_0000000000001051 crossref_primary_10_1097_BPO_0000000000001575 crossref_primary_10_1055_a_1306_4684 crossref_primary_10_1016_j_bone_2021_115914 crossref_primary_10_1016_j_eclinm_2019_06_004 crossref_primary_10_1172_JCI71101 crossref_primary_10_1016_j_bone_2020_115250 crossref_primary_10_1136_bjsports_2013_093218 crossref_primary_10_1002_14651858_CD010750_pub2 crossref_primary_10_1007_s00198_018_4448_2 crossref_primary_10_1016_j_bone_2019_06_011 crossref_primary_10_1007_s00198_016_3723_3 crossref_primary_10_1016_j_reuma_2018_05_004 crossref_primary_10_1210_clinem_dgad657 crossref_primary_10_1007_s00223_024_01205_4 crossref_primary_10_1038_pr_2015_230 crossref_primary_10_1210_clinem_dgae507 crossref_primary_10_1016_j_reumae_2018_05_001 crossref_primary_10_1186_s40200_014_0109_y crossref_primary_10_1530_EJE_14_0017 crossref_primary_10_1111_cen_12367 crossref_primary_10_1016_j_matbio_2021_03_001 crossref_primary_10_1186_1471_2474_15_428 crossref_primary_10_1210_endrev_bnab017 crossref_primary_10_1038_s41431_024_01645_4 crossref_primary_10_1177_1759720X20969262 crossref_primary_10_3390_ijerph19031563 crossref_primary_10_1172_JCI74230 crossref_primary_10_1007_s00198_017_4094_0 crossref_primary_10_18821_1560_9561_2016_19_5_282_287 crossref_primary_10_55275_JPOSNA_2019_33 crossref_primary_10_1016_j_etap_2016_01_015 crossref_primary_10_1016_j_ejmg_2021_104342 crossref_primary_10_1016_j_cca_2016_09_019 crossref_primary_10_1017_S1431927616000726 crossref_primary_10_1055_a_1233_9812 crossref_primary_10_1172_JCI152571 crossref_primary_10_3171_2014_11_PEDS14113 crossref_primary_10_3390_ijms24119416 crossref_primary_10_1016_j_endinu_2018_05_015 crossref_primary_10_1210_jc_2014_1371 crossref_primary_10_1371_journal_pone_0107594 crossref_primary_10_1179_2295333714Y_0000000094 crossref_primary_10_1007_s11914_020_00621_3 crossref_primary_10_2490_jjrmc_51_288 crossref_primary_10_1177_2040622317739538 crossref_primary_10_1007_s00223_024_01202_7 crossref_primary_10_5435_JAAOS_D_23_00889 crossref_primary_10_1097_MED_0000000000000111 crossref_primary_10_1186_s10020_024_00838_3 crossref_primary_10_3233_JND_230176 crossref_primary_10_1016_j_bone_2014_12_011 crossref_primary_10_1016_S0140_6736_13_61531_7 crossref_primary_10_1210_clinem_dgad035 crossref_primary_10_1002_jbm4_10174 crossref_primary_10_1186_s13023_024_03433_1 crossref_primary_10_1097_MED_0000000000000106 crossref_primary_10_1186_1824_7288_40_55 crossref_primary_10_12688_f1000research_6398_1 crossref_primary_10_1186_s12891_017_1922_5 crossref_primary_10_4158_EP161322_OR crossref_primary_10_1016_j_ejrad_2018_06_001 crossref_primary_10_1542_pir_2023_006041 crossref_primary_10_1007_s40618_024_02380_9 crossref_primary_10_1002_ajmg_a_37734 crossref_primary_10_1055_a_1730_5412 crossref_primary_10_1159_000369582 crossref_primary_10_1517_21678707_2016_1148596 crossref_primary_10_1016_j_jocd_2014_01_005 crossref_primary_10_1530_EJE_14_0865 crossref_primary_10_1002_jbmr_2805 crossref_primary_10_1002_jbmr_2410 crossref_primary_10_3389_fendo_2023_1266986 crossref_primary_10_1007_s11914_016_0299_y |
| Cites_doi | 10.1080/01621459.1958.10501452 10.1111/j.1399-0004.1989.tb03198.x 10.1111/j.1651-2227.1998.tb01388.x 10.1136/jmg.16.2.101 10.1002/14651858.CD005088.pub2 10.1016/S0140-6736(04)16101-1 10.1056/NEJMct1004903 10.1016/j.bone.2006.04.004 10.1007/s00198-011-1658-2 10.1359/JBMR.041232 10.1007/s004310051322 10.1210/jc.2010-0636 10.1016/S0022-3476(97)70074-X 10.1359/JBMR.050109 10.1056/NEJM199810013391402 10.1002/jbmr.5650080915 10.1016/j.earlhumdev.2010.08.002 10.1359/jbmr.090213 10.1359/jbmr.090712 10.1016/j.bone.2004.07.003 10.1016/j.csda.2008.04.009 10.1136/adc.2007.125468 10.1097/01.bpo.0000176162.78980.ed 10.1136/adc.2006.096552 |
| ContentType | Journal Article |
| Copyright | 2013 Elsevier Ltd Elsevier Ltd 2014 INIST-CNRS Copyright © 2013 Elsevier Ltd. All rights reserved. Copyright Elsevier Limited Oct 26, 2013 |
| Copyright_xml | – notice: 2013 Elsevier Ltd – notice: Elsevier Ltd – notice: 2014 INIST-CNRS – notice: Copyright © 2013 Elsevier Ltd. All rights reserved. – notice: Copyright Elsevier Limited Oct 26, 2013 |
| DBID | FBQ AAYXX CITATION IQODW CGR CUY CVF ECM EIF NPM 3V. 7QL 7QP 7RV 7TK 7U7 7U9 7X7 7XB 88A 88C 88E 88G 88I 8AF 8AO 8C1 8C2 8FE 8FH 8FI 8FJ 8FK 8G5 ABUWG AEUYN AFKRA AN0 ASE AZQEC BBNVY BEC BENPR BHPHI C1K CCPQU DWQXO FPQ FYUFA GHDGH GNUQQ GUQSH H94 HCIFZ K6X K9- K9. KB0 KB~ LK8 M0R M0S M0T M1P M2M M2O M2P M7N M7P MBDVC NAPCQ PHGZM PHGZT PJZUB PKEHL PPXIY PQEST PQGLB PQQKQ PQUKI PRINS PSYQQ Q9U S0X 7X8 7U1 7S9 L.6 ADTPV AOWAS |
| DOI | 10.1016/S0140-6736(13)61091-0 |
| DatabaseName | AGRIS CrossRef Pascal-Francis Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed ProQuest Central (Corporate) Bacteriology Abstracts (Microbiology B) Calcium & Calcified Tissue Abstracts Nursing & Allied Health Database (Proquest) Neurosciences Abstracts Toxicology Abstracts Virology and AIDS Abstracts Health & Medical Collection (Proquest) ProQuest Central (purchase pre-March 2016) Biology Database (Alumni Edition) Healthcare Administration Database (Alumni) Medical Database (Alumni Edition) Psychology Database (Alumni) Science Database (Alumni Edition) STEM Database ProQuest Pharma Collection Proquest Public Health Database Lancet Titles ProQuest SciTech Collection ProQuest Natural Science Collection Hospital Premium Collection Hospital Premium Collection (Alumni Edition) ProQuest Central (Alumni) (purchase pre-March 2016) ProQuest Research Library ProQuest Central ProQuest One Sustainability ProQuest Central UK/Ireland British Nursing Database (Proquest) British Nursing Index ProQuest Central Essentials Biological Science Collection eLibrary ProQuest Central Natural Science Collection Environmental Sciences and Pollution Management ProQuest One ProQuest Central British Nursing Index (BNI) (1985 to Present) Health Research Premium Collection Health Research Premium Collection (Alumni) ProQuest Central Student ProQuest Research Library AIDS and Cancer Research Abstracts SciTech Premium Collection (via ProQuest) British Nursing Index Consumer Health Database (Alumni Edition) ProQuest Health & Medical Complete (Alumni) Nursing & Allied Health Database (Alumni Edition) ProQuest Newsstand Professional ProQuest Biological Science Collection Consumer Health Database ProQuest Health & Medical Collection Healthcare Administration Database Medical Database Psychology Collection (Proquest) Research Library Science Database (via ProQuest SciTech Premium Collection) Algology Mycology and Protozoology Abstracts (Microbiology C) Biological Science Database (Proquest) Research Library (Corporate) Nursing & Allied Health Premium ProQuest Central Premium ProQuest One Academic (New) ProQuest Health & Medical Research Collection ProQuest One Academic Middle East (New) ProQuest One Health & Nursing ProQuest One Academic Eastern Edition (DO NOT USE) ProQuest One Applied & Life Sciences ProQuest One Academic ProQuest One Academic UKI Edition ProQuest Central China ProQuest One Psychology ProQuest Central Basic SIRS Editorial MEDLINE - Academic Risk Abstracts AGRICOLA AGRICOLA - Academic SwePub SwePub Articles |
| DatabaseTitle | CrossRef MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) ProQuest One Psychology Research Library Prep ProQuest Central Student ProQuest Central Essentials Lancet Titles elibrary ProQuest AP Science SciTech Premium Collection ProQuest Central China Environmental Sciences and Pollution Management ProQuest One Applied & Life Sciences ProQuest One Sustainability Health Research Premium Collection Natural Science Collection Health & Medical Research Collection Biological Science Collection ProQuest Central (New) ProQuest Medical Library (Alumni) ProQuest Newsstand Professional Virology and AIDS Abstracts ProQuest Science Journals (Alumni Edition) ProQuest Biological Science Collection ProQuest Family Health ProQuest One Academic Eastern Edition ProQuest Hospital Collection Health Research Premium Collection (Alumni) Biological Science Database Neurosciences Abstracts ProQuest Hospital Collection (Alumni) Nursing & Allied Health Premium ProQuest Health & Medical Complete ProQuest One Academic UKI Edition ProQuest Health Management (Alumni Edition) ProQuest Nursing & Allied Health Source (Alumni) ProQuest One Academic Calcium & Calcified Tissue Abstracts ProQuest One Academic (New) ProQuest One Academic Middle East (New) SIRS Editorial ProQuest Health & Medical Complete (Alumni) ProQuest Central (Alumni Edition) ProQuest One Community College ProQuest One Health & Nursing Research Library (Alumni Edition) ProQuest Natural Science Collection ProQuest Pharma Collection ProQuest Family Health (Alumni Edition) ProQuest Biology Journals (Alumni Edition) ProQuest Central ProQuest Health & Medical Research Collection Health and Medicine Complete (Alumni Edition) ProQuest Central Korea Bacteriology Abstracts (Microbiology B) Algology Mycology and Protozoology Abstracts (Microbiology C) AIDS and Cancer Research Abstracts ProQuest Research Library ProQuest Public Health ProQuest Central Basic Toxicology Abstracts ProQuest Science Journals British Nursing Index with Full Text ProQuest Health Management British Nursing Index ProQuest Nursing & Allied Health Source ProQuest Psychology Journals (Alumni) ProQuest SciTech Collection ProQuest Medical Library ProQuest Psychology Journals ProQuest Central (Alumni) MEDLINE - Academic Risk Abstracts AGRICOLA AGRICOLA - Academic |
| DatabaseTitleList | MEDLINE - Academic Risk Abstracts AGRICOLA Risk Abstracts ProQuest One Psychology MEDLINE Risk Abstracts |
| Database_xml | – sequence: 1 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: EIF name: MEDLINE url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search sourceTypes: Index Database – sequence: 3 dbid: BENPR name: ProQuest Central url: http://www.proquest.com/pqcentral?accountid=15518 sourceTypes: Aggregation Database – sequence: 4 dbid: FBQ name: AGRIS url: http://www.fao.org/agris/Centre.asp?Menu_1ID=DB&Menu_2ID=DB1&Language=EN&Content=http://www.fao.org/agris/search?Language=EN sourceTypes: Publisher |
| DeliveryMethod | fulltext_linktorsrc |
| Discipline | Medicine |
| EISSN | 1474-547X |
| EndPage | 1432 |
| ExternalDocumentID | oai_swepub_ki_se_527699 3108742771 23927913 27816481 10_1016_S0140_6736_13_61091_0 US201500130570 S0140673613610910 1_s2_0_S0140673613610910 |
| Genre | Multicenter Study Randomized Controlled Trial Research Support, Non-U.S. Gov't Journal Article |
| GrantInformation | Alliance for Better Bone Health (Warner Chilcott and Sanofi). |
| GroupedDBID | --- --K --M .1- .55 .CO .FO 0R~ 123 1B1 1P~ 1RT 1~5 29L 4.4 457 4G. 53G 5VS 7-5 71M 7RV 7X7 88E 88I 8AF 8AO 8C1 8C2 8FE 8FH 8FI 8FJ 8G5 9JM AABNK AAEDT AAEDW AAIKJ AAKOC AALRI AAMRU AAQFI AAQQT AATTM AAXKI AAXUO AAYWO ABBQC ABCQX ABFNM ABIVO ABJNI ABLJU ABMAC ABMZM ABOCM ABUWG ACGFS ACGOD ACIEU ACIUM ACPRK ACRLP ACVFH ADBBV ADCNI AEIPS AEKER AENEX AEUPX AEUYN AEVXI AFKRA AFPUW AFRAH AFRHN AFTJW AFXIZ AGAPS AGCQF AGHFR AHHHB AHMBA AIIUN AITUG AJRQY AJUYK AKBMS AKRWK AKYEP ALMA_UNASSIGNED_HOLDINGS AMRAJ AN0 ANZVX APXCP AQUVI AXJTR AZQEC BBNVY BCU BEC BENPR BHPHI BKEYQ BKNYI BKOJK BKOMP BNPGV BNQBC BPHCQ BVXVI CCPQU CS3 DU5 DWQXO EAU EBS EFJIC EFKBS EJD EO8 EO9 EP2 EP3 EWM EX3 F5P FD8 FDB FIRID FNPLU FYGXN FYUFA G-2 G-Q GBLVA GNUQQ GUQSH HCIFZ HMCUK IHE J1W K-O K9- KOM L7B LK8 LZ2 M0R M0T M1P M2M M2O M2P M41 M7P MJL MO0 N9A NAPCQ O-L O9- OD. OO~ OZT P-8 P-9 P2P PC. PHGZM PHGZT PJZUB PPXIY PQGLB PQQKQ PRG PROAC PSQYO PSYQQ PUEGO R2- ROL RPZ S0X SAD SDG SEL SES SJFOW SJN SPCBC SSH SSZ T5K TLN TWZ UAP UBE UKHRP UQL UV1 WOW X7M XAX XDU YYM Z5R ZMT .GJ 04C 3EH 3O- 3V. 41~ 88A 8WZ A6W AACTN AAEJM AAKAS AAQXK AAYOK ABDBF ABTAH ABWVN ACRPL ACRZS ACUHS ADMUD ADNMO ADZCM AFCTW AFFNX AFKWA AHQJS AJJEV AJOXV AKVCP ALIPV AMFUW ARTTT ASPBG AVWKF AZFZN D0S EAP EAS EAZ EBC EBD EBU EGS EHN EIHBH EMB EMK EMOBN ENC EPL EPS EPT ESX EVS FEDTE FGOYB HVGLF HZ~ J5H M0L MVM OVD PKN Q~Q RIG SDF SV3 TEORI TH9 UHU WOQ WUQ XPP YYQ ZGI ZXP ZY4 ~G0 ABLVK ABYKQ AHPSJ AJBFU XFK ZA5 AEQTP FBQ NHB Y6R AAYXX ADXHL AGQPQ AGRNS AIGII CITATION IQODW CGR CUY CVF ECM EIF NPM 7QL 7QP 7TK 7U7 7U9 7XB 8FK ASE C1K FPQ H94 K6X K9. KB~ M7N MBDVC PKEHL PQEST PQUKI PRINS Q9U 7X8 ACLOT ~HD 7U1 7S9 L.6 ADTPV AOWAS |
| ID | FETCH-LOGICAL-c726t-17c7ef27293dca213793a204ca21b5abfb85bd49125247b6c96be5c6339ea9363 |
| IEDL.DBID | 7X7 |
| ISSN | 0140-6736 1474-547X |
| IngestDate | Wed Sep 24 03:29:03 EDT 2025 Sat Sep 27 21:18:57 EDT 2025 Fri Sep 05 12:45:51 EDT 2025 Sat Sep 27 21:12:01 EDT 2025 Sun Sep 28 02:41:01 EDT 2025 Sun Sep 28 11:11:26 EDT 2025 Sat Aug 23 12:43:15 EDT 2025 Mon Jul 21 05:49:52 EDT 2025 Mon Jul 21 09:13:56 EDT 2025 Tue Jul 01 03:16:13 EDT 2025 Thu Apr 24 23:03:09 EDT 2025 Wed Dec 27 19:17:46 EST 2023 Fri Feb 23 02:30:16 EST 2024 Sun Feb 23 10:19:31 EST 2025 Tue Aug 26 18:33:01 EDT 2025 |
| IsPeerReviewed | true |
| IsScholarly | true |
| Issue | 9902 |
| Keywords | Human Antiosteoporotic Diseases of the osteoarticular system Antiresorptive agent Diphosphonic acid derivatives Bisphosphonates Randomized controlled trial Genetic disease Medicine Antiosteoclastic agent Risedronic acid Double blind study Osteogenesis imperfecta Clinical trial Osteochondrodysplasia Child |
| Language | English |
| License | CC BY 4.0 Copyright © 2013 Elsevier Ltd. All rights reserved. |
| LinkModel | DirectLink |
| MergedId | FETCHMERGED-LOGICAL-c726t-17c7ef27293dca213793a204ca21b5abfb85bd49125247b6c96be5c6339ea9363 |
| Notes | http://dx.doi.org/10.1016/S0140-6736(13)61091-0 ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 14 content type line 23 ObjectType-Undefined-3 ObjectType-Article-2 ObjectType-Feature-1 |
| PMID | 23927913 |
| PQID | 1444977978 |
| PQPubID | 23462 |
| PageCount | 9 |
| ParticipantIDs | swepub_primary_oai_swepub_ki_se_527699 proquest_miscellaneous_1678558600 proquest_miscellaneous_1560119545 proquest_miscellaneous_1468360109 proquest_miscellaneous_1464507492 proquest_miscellaneous_1450182607 proquest_journals_1444977978 pubmed_primary_23927913 pascalfrancis_primary_27816481 crossref_citationtrail_10_1016_S0140_6736_13_61091_0 crossref_primary_10_1016_S0140_6736_13_61091_0 fao_agris_US201500130570 elsevier_sciencedirect_doi_10_1016_S0140_6736_13_61091_0 elsevier_clinicalkeyesjournals_1_s2_0_S0140673613610910 elsevier_clinicalkey_doi_10_1016_S0140_6736_13_61091_0 |
| ProviderPackageCode | CITATION AAYXX |
| PublicationCentury | 2000 |
| PublicationDate | 2013-10-26 |
| PublicationDateYYYYMMDD | 2013-10-26 |
| PublicationDate_xml | – month: 10 year: 2013 text: 2013-10-26 day: 26 |
| PublicationDecade | 2010 |
| PublicationPlace | Kidlington |
| PublicationPlace_xml | – name: Kidlington – name: England – name: London |
| PublicationTitle | The Lancet (British edition) |
| PublicationTitleAlternate | Lancet |
| PublicationYear | 2013 |
| Publisher | Elsevier Ltd Elsevier Elsevier Limited |
| Publisher_xml | – name: Elsevier Ltd – name: Elsevier – name: Elsevier Limited |
| References | Land, Rauch, Munns, Sahebjam, Glorieux (bib25) 2006; 39 Gatti, Antoniazzi, Prizzi (bib16) 2005; 20 Arundel, Bishop (bib6) 2010 Kaplan, Meier (bib27) 1958; 53 DiMeglio, Ford, McClintock, Peacock (bib13) 2004; 35 Glorieux (bib23) 2000; 13 Plotkin, Rauch, Bishop (bib12) 2000; 85 Kuurila, Grénman, Johansson, Kaitila (bib3) 2000; 159 Bishop (bib4) 2010; 86 Bembi, Parma, Bottega (bib9) 1997; 131 Senthilnathan, Walker, Bishop (bib14) 2008; 93 Seikaly, Kopanati, Salhab (bib20) 2005; 25 Bradbury, Barlow, Geoghegan (bib29) 2012; 23 Ward, Rauch, Whyte (bib21) 2011; 96 Andersen, Hauge (bib2) 1989; 36 Bishop (bib5) 2009 Rauch, Munns, Land, Cheung, Glorieux (bib15) 2009; 24 Sillence, Senn, Danks (bib1) 1979; 16 Bishop, Harrison, Ahmed (bib22) 2010; 25 Phillipi, Remmington, Steiner (bib19) 2008; 4 Greulich, Pyle (bib26) 1959 Letocha, Cintas, Troendle (bib17) 2005; 20 Jahn-Eimermacher (bib28) 2008; 52 Aström, Söderhäll (bib8) 1998; 87 Aström, Jorulf, Söderhäll (bib11) 2007; 92 Favus (bib7) 2010; 363 Glorieux, Bishop, Plotkin, Chabot, Lanoue, Travers (bib10) 1998; 339 Sakkers, Kok, Engelbert (bib18) 2004; 363 Genant, Wu, van Kuijk, Nevitt (bib24) 1993; 8 Seikaly (10.1016/S0140-6736(13)61091-0_bib20) 2005; 25 Ward (10.1016/S0140-6736(13)61091-0_bib21) 2011; 96 Bishop (10.1016/S0140-6736(13)61091-0_bib5) 2009 Sakkers (10.1016/S0140-6736(13)61091-0_bib18) 2004; 363 Sillence (10.1016/S0140-6736(13)61091-0_bib1) 1979; 16 Aström (10.1016/S0140-6736(13)61091-0_bib11) 2007; 92 Letocha (10.1016/S0140-6736(13)61091-0_bib17) 2005; 20 Jahn-Eimermacher (10.1016/S0140-6736(13)61091-0_bib28) 2008; 52 Rauch (10.1016/S0140-6736(13)61091-0_bib15) 2009; 24 Bishop (10.1016/S0140-6736(13)61091-0_bib4) 2010; 86 Andersen (10.1016/S0140-6736(13)61091-0_bib2) 1989; 36 Gatti (10.1016/S0140-6736(13)61091-0_bib16) 2005; 20 Greulich (10.1016/S0140-6736(13)61091-0_bib26) 1959 Bishop (10.1016/S0140-6736(13)61091-0_bib22) 2010; 25 Bradbury (10.1016/S0140-6736(13)61091-0_bib29) 2012; 23 Phillipi (10.1016/S0140-6736(13)61091-0_bib19) 2008; 4 Arundel (10.1016/S0140-6736(13)61091-0_bib6) 2010 Plotkin (10.1016/S0140-6736(13)61091-0_bib12) 2000; 85 Favus (10.1016/S0140-6736(13)61091-0_bib7) 2010; 363 Land (10.1016/S0140-6736(13)61091-0_bib25) 2006; 39 Genant (10.1016/S0140-6736(13)61091-0_bib24) 1993; 8 Kaplan (10.1016/S0140-6736(13)61091-0_bib27) 1958; 53 Aström (10.1016/S0140-6736(13)61091-0_bib8) 1998; 87 Kuurila (10.1016/S0140-6736(13)61091-0_bib3) 2000; 159 Senthilnathan (10.1016/S0140-6736(13)61091-0_bib14) 2008; 93 Glorieux (10.1016/S0140-6736(13)61091-0_bib23) 2000; 13 Glorieux (10.1016/S0140-6736(13)61091-0_bib10) 1998; 339 DiMeglio (10.1016/S0140-6736(13)61091-0_bib13) 2004; 35 Bembi (10.1016/S0140-6736(13)61091-0_bib9) 1997; 131 23927912 - Lancet. 2013 Oct 26;382(9902):1388-9 |
| References_xml | – volume: 363 start-page: 1427 year: 2004 end-page: 1431 ident: bib18 article-title: Skeletal effects and functional outcome with olpadronate in children with osteogenesis imperfecta: a 2-year randomised placebo-controlled study publication-title: Lancet – start-page: 215 year: 2010 end-page: 230 ident: bib6 article-title: Osteogenesis imperfecta publication-title: Bone and development – volume: 25 start-page: 786 year: 2005 end-page: 791 ident: bib20 article-title: Impact of alendronate on quality of life in children with osteogenesis imperfecta publication-title: J Pediatr Orthop – volume: 23 start-page: 285 year: 2012 end-page: 294 ident: bib29 article-title: Risedronate in adults with osteogenesis imperfecta type I: increased bone mineral density and decreased bone turnover, but high fracture rate persists publication-title: Osteoporos Int – volume: 87 start-page: 64 year: 1998 end-page: 68 ident: bib8 article-title: Beneficial effect of bisphosphonate during five years of treatment of severe osteogenesis imperfecta publication-title: Acta Paediatr – volume: 86 start-page: 743 year: 2010 end-page: 746 ident: bib4 article-title: Characterising and treating osteogenesis imperfecta publication-title: Early Hum Dev – volume: 96 start-page: 355 year: 2011 end-page: 364 ident: bib21 article-title: Alendronate for the treatment of pediatric osteogenesis imperfecta: a randomized placebo-controlled study publication-title: J Clin Endocrinol Metab – year: 1959 ident: bib26 publication-title: Radiographic atlas of skeletal development of the hand and wrist – start-page: 157 year: 2009 end-page: 168 ident: bib5 article-title: Primary osteoporosis publication-title: Calcium and bone disorders in children and adolescents – volume: 93 start-page: 398 year: 2008 end-page: 400 ident: bib14 article-title: Two doses of pamidronate in infants with osteogenesis imperfecta publication-title: Arch Dis Child – volume: 39 start-page: 901 year: 2006 end-page: 906 ident: bib25 article-title: Vertebral morphometry in children and adolescents with osteogenesis imperfecta: effect of intravenous pamidronate treatment publication-title: Bone – volume: 52 start-page: 4989 year: 2008 end-page: 4997 ident: bib28 article-title: Comparison of the Andersen–Gill model with poisson and negative binomial regression on recurrent event data publication-title: Comput Stat Data Anal – volume: 92 start-page: 332 year: 2007 end-page: 338 ident: bib11 article-title: Intravenous pamidronate treatment of infants with severe osteogenesis imperfecta publication-title: Arch Dis Child – volume: 24 start-page: 1282 year: 2009 end-page: 1289 ident: bib15 article-title: Risedronate in the treatment of mild pediatric osteogenesis imperfecta: a randomized placebo-controlled study publication-title: J Bone Miner Res – volume: 131 start-page: 622 year: 1997 end-page: 625 ident: bib9 article-title: Intravenous pamidronate treatment in osteogenesis imperfecta publication-title: J Pediatr – volume: 8 start-page: 1137 year: 1993 end-page: 1148 ident: bib24 article-title: Vertebral fracture assessment using a semiquantitative technique publication-title: J Bone Miner Res – volume: 85 start-page: 1846 year: 2000 end-page: 1850 ident: bib12 article-title: Pamidronate treatment of severe osteogenesis imperfecta in children under 3 years of age publication-title: J Clin Endocrinol Metab – volume: 36 start-page: 250 year: 1989 end-page: 255 ident: bib2 article-title: Osteogenesis imperfecta: a genetic, radiological, and epidemiological study publication-title: Clin Genet – volume: 16 start-page: 101 year: 1979 end-page: 116 ident: bib1 article-title: Genetic heterogeneity in osteogenesis imperfecta publication-title: J Med Genet – volume: 4 year: 2008 ident: bib19 article-title: Bisphosphonate therapy for osteogenesis imperfecta publication-title: Cochrane Database Syst Rev – volume: 13 start-page: 989 year: 2000 end-page: 992 ident: bib23 article-title: Bisphosphonate therapy for severe osteogenesis imperfecta publication-title: J Pediatr Endocrinol Metab – volume: 363 start-page: 2027 year: 2010 end-page: 2035 ident: bib7 article-title: Bisphosphonates for osteoporosis publication-title: N Engl J Med – volume: 20 start-page: 977 year: 2005 end-page: 986 ident: bib17 article-title: Controlled trial of pamidronate in children with types III and IV osteogenesis imperfecta confirms vertebral gains but not short-term functional improvement publication-title: J Bone Miner Res – volume: 53 start-page: 457 year: 1958 end-page: 481 ident: bib27 article-title: Nonparametric estimation from incomplete observations publication-title: J Am Stat Assoc – volume: 20 start-page: 758 year: 2005 end-page: 763 ident: bib16 article-title: Intravenous neridronate in children with osteogenesis imperfecta: a randomized controlled study publication-title: J Bone Miner Res – volume: 25 start-page: 32 year: 2010 end-page: 40 ident: bib22 article-title: A randomized, controlled dose-ranging study of risedronate in children with moderate and severe osteogenesis imperfecta publication-title: J Bone Miner Res – volume: 35 start-page: 1038 year: 2004 end-page: 1045 ident: bib13 article-title: Intravenous pamidronate treatment of children under 36 months of age with osteogenesis imperfecta publication-title: Bone – volume: 339 start-page: 947 year: 1998 end-page: 952 ident: bib10 article-title: Cyclic administration of pamidronate in children with severe osteogenesis imperfecta publication-title: N Engl J Med – volume: 159 start-page: 515 year: 2000 end-page: 519 ident: bib3 article-title: Hearing loss in children with osteogenesis imperfecta publication-title: Eur J Pediatr – volume: 85 start-page: 1846 year: 2000 ident: 10.1016/S0140-6736(13)61091-0_bib12 article-title: Pamidronate treatment of severe osteogenesis imperfecta in children under 3 years of age publication-title: J Clin Endocrinol Metab – volume: 53 start-page: 457 year: 1958 ident: 10.1016/S0140-6736(13)61091-0_bib27 article-title: Nonparametric estimation from incomplete observations publication-title: J Am Stat Assoc doi: 10.1080/01621459.1958.10501452 – volume: 36 start-page: 250 year: 1989 ident: 10.1016/S0140-6736(13)61091-0_bib2 article-title: Osteogenesis imperfecta: a genetic, radiological, and epidemiological study publication-title: Clin Genet doi: 10.1111/j.1399-0004.1989.tb03198.x – volume: 87 start-page: 64 year: 1998 ident: 10.1016/S0140-6736(13)61091-0_bib8 article-title: Beneficial effect of bisphosphonate during five years of treatment of severe osteogenesis imperfecta publication-title: Acta Paediatr doi: 10.1111/j.1651-2227.1998.tb01388.x – volume: 16 start-page: 101 year: 1979 ident: 10.1016/S0140-6736(13)61091-0_bib1 article-title: Genetic heterogeneity in osteogenesis imperfecta publication-title: J Med Genet doi: 10.1136/jmg.16.2.101 – volume: 4 year: 2008 ident: 10.1016/S0140-6736(13)61091-0_bib19 article-title: Bisphosphonate therapy for osteogenesis imperfecta publication-title: Cochrane Database Syst Rev doi: 10.1002/14651858.CD005088.pub2 – volume: 363 start-page: 1427 year: 2004 ident: 10.1016/S0140-6736(13)61091-0_bib18 article-title: Skeletal effects and functional outcome with olpadronate in children with osteogenesis imperfecta: a 2-year randomised placebo-controlled study publication-title: Lancet doi: 10.1016/S0140-6736(04)16101-1 – volume: 363 start-page: 2027 year: 2010 ident: 10.1016/S0140-6736(13)61091-0_bib7 article-title: Bisphosphonates for osteoporosis publication-title: N Engl J Med doi: 10.1056/NEJMct1004903 – volume: 39 start-page: 901 year: 2006 ident: 10.1016/S0140-6736(13)61091-0_bib25 article-title: Vertebral morphometry in children and adolescents with osteogenesis imperfecta: effect of intravenous pamidronate treatment publication-title: Bone doi: 10.1016/j.bone.2006.04.004 – volume: 23 start-page: 285 year: 2012 ident: 10.1016/S0140-6736(13)61091-0_bib29 article-title: Risedronate in adults with osteogenesis imperfecta type I: increased bone mineral density and decreased bone turnover, but high fracture rate persists publication-title: Osteoporos Int doi: 10.1007/s00198-011-1658-2 – volume: 20 start-page: 758 year: 2005 ident: 10.1016/S0140-6736(13)61091-0_bib16 article-title: Intravenous neridronate in children with osteogenesis imperfecta: a randomized controlled study publication-title: J Bone Miner Res doi: 10.1359/JBMR.041232 – start-page: 215 year: 2010 ident: 10.1016/S0140-6736(13)61091-0_bib6 article-title: Osteogenesis imperfecta – volume: 159 start-page: 515 year: 2000 ident: 10.1016/S0140-6736(13)61091-0_bib3 article-title: Hearing loss in children with osteogenesis imperfecta publication-title: Eur J Pediatr doi: 10.1007/s004310051322 – year: 1959 ident: 10.1016/S0140-6736(13)61091-0_bib26 – volume: 96 start-page: 355 year: 2011 ident: 10.1016/S0140-6736(13)61091-0_bib21 article-title: Alendronate for the treatment of pediatric osteogenesis imperfecta: a randomized placebo-controlled study publication-title: J Clin Endocrinol Metab doi: 10.1210/jc.2010-0636 – volume: 131 start-page: 622 year: 1997 ident: 10.1016/S0140-6736(13)61091-0_bib9 article-title: Intravenous pamidronate treatment in osteogenesis imperfecta publication-title: J Pediatr doi: 10.1016/S0022-3476(97)70074-X – volume: 20 start-page: 977 year: 2005 ident: 10.1016/S0140-6736(13)61091-0_bib17 article-title: Controlled trial of pamidronate in children with types III and IV osteogenesis imperfecta confirms vertebral gains but not short-term functional improvement publication-title: J Bone Miner Res doi: 10.1359/JBMR.050109 – volume: 13 start-page: 989 issue: suppl 2 year: 2000 ident: 10.1016/S0140-6736(13)61091-0_bib23 article-title: Bisphosphonate therapy for severe osteogenesis imperfecta publication-title: J Pediatr Endocrinol Metab – volume: 339 start-page: 947 year: 1998 ident: 10.1016/S0140-6736(13)61091-0_bib10 article-title: Cyclic administration of pamidronate in children with severe osteogenesis imperfecta publication-title: N Engl J Med doi: 10.1056/NEJM199810013391402 – volume: 8 start-page: 1137 year: 1993 ident: 10.1016/S0140-6736(13)61091-0_bib24 article-title: Vertebral fracture assessment using a semiquantitative technique publication-title: J Bone Miner Res doi: 10.1002/jbmr.5650080915 – volume: 86 start-page: 743 year: 2010 ident: 10.1016/S0140-6736(13)61091-0_bib4 article-title: Characterising and treating osteogenesis imperfecta publication-title: Early Hum Dev doi: 10.1016/j.earlhumdev.2010.08.002 – volume: 24 start-page: 1282 year: 2009 ident: 10.1016/S0140-6736(13)61091-0_bib15 article-title: Risedronate in the treatment of mild pediatric osteogenesis imperfecta: a randomized placebo-controlled study publication-title: J Bone Miner Res doi: 10.1359/jbmr.090213 – volume: 25 start-page: 32 year: 2010 ident: 10.1016/S0140-6736(13)61091-0_bib22 article-title: A randomized, controlled dose-ranging study of risedronate in children with moderate and severe osteogenesis imperfecta publication-title: J Bone Miner Res doi: 10.1359/jbmr.090712 – volume: 35 start-page: 1038 year: 2004 ident: 10.1016/S0140-6736(13)61091-0_bib13 article-title: Intravenous pamidronate treatment of children under 36 months of age with osteogenesis imperfecta publication-title: Bone doi: 10.1016/j.bone.2004.07.003 – volume: 52 start-page: 4989 year: 2008 ident: 10.1016/S0140-6736(13)61091-0_bib28 article-title: Comparison of the Andersen–Gill model with poisson and negative binomial regression on recurrent event data publication-title: Comput Stat Data Anal doi: 10.1016/j.csda.2008.04.009 – volume: 93 start-page: 398 year: 2008 ident: 10.1016/S0140-6736(13)61091-0_bib14 article-title: Two doses of pamidronate in infants with osteogenesis imperfecta publication-title: Arch Dis Child doi: 10.1136/adc.2007.125468 – volume: 25 start-page: 786 year: 2005 ident: 10.1016/S0140-6736(13)61091-0_bib20 article-title: Impact of alendronate on quality of life in children with osteogenesis imperfecta publication-title: J Pediatr Orthop doi: 10.1097/01.bpo.0000176162.78980.ed – volume: 92 start-page: 332 year: 2007 ident: 10.1016/S0140-6736(13)61091-0_bib11 article-title: Intravenous pamidronate treatment of infants with severe osteogenesis imperfecta publication-title: Arch Dis Child doi: 10.1136/adc.2006.096552 – start-page: 157 year: 2009 ident: 10.1016/S0140-6736(13)61091-0_bib5 article-title: Primary osteoporosis – reference: 23927912 - Lancet. 2013 Oct 26;382(9902):1388-9 |
| SSID | ssj0004605 |
| Score | 2.5044906 |
| Snippet | Children with osteogenesis imperfecta are often treated with intravenous bisphosphonates. We aimed to assess the safety and efficacy of risedronate, an orally... Summary Background Children with osteogenesis imperfecta are often treated with intravenous bisphosphonates. We aimed to assess the safety and efficacy of... BACKGROUND: Children with osteogenesis imperfecta are often treated with intravenous bisphosphonates. We aimed to assess the safety and efficacy of... Background Children with osteogenesis imperfecta are often treated with intravenous bisphosphonates. We aimed to assess the safety and efficacy of risedronate,... Background: Children with osteogenesis imperfecta are often treated with intravenous bisphosphonates. We aimed to assess the safety and efficacy of... |
| SourceID | swepub proquest pubmed pascalfrancis crossref fao elsevier |
| SourceType | Open Access Repository Aggregation Database Index Database Enrichment Source Publisher |
| StartPage | 1424 |
| SubjectTerms | Administration, Oral Adolescent Age Alkaline Phosphatase - metabolism Analysis of Variance Biological and medical sciences Bisphosphonates Bone density Bone Density - drug effects Bone Density Conservation Agents - administration & dosage Bone Density Conservation Agents - adverse effects Bone diseases bone formation Bone mineral density Child Child, Preschool children Collagen - metabolism Diseases of the osteoarticular system Double-Blind Method Drug Administration Schedule drugs Etidronic Acid - administration & dosage Etidronic Acid - adverse effects Etidronic Acid - analogs & derivatives Female Fractures General aspects human resources Humans Internal Medicine intravenous injection lumbar spine Male Malformations and congenital and or hereditary diseases involving bones. Joint deformations Medical sciences Older people oral administration Osteogenesis Imperfecta - drug therapy Osteogenesis Imperfecta - physiopathology Osteoporosis Pain patients Risedronate Sodium risk Spine Treatment Outcome |
| Title | Risedronate in children with osteogenesis imperfecta: a randomised, double-blind, placebo-controlled trial |
| URI | https://www.clinicalkey.com/#!/content/1-s2.0-S0140673613610910 https://www.clinicalkey.es/playcontent/1-s2.0-S0140673613610910 https://dx.doi.org/10.1016/S0140-6736(13)61091-0 https://www.ncbi.nlm.nih.gov/pubmed/23927913 https://www.proquest.com/docview/1444977978 https://www.proquest.com/docview/1450182607 https://www.proquest.com/docview/1464507492 https://www.proquest.com/docview/1468360109 https://www.proquest.com/docview/1560119545 https://www.proquest.com/docview/1678558600 http://kipublications.ki.se/Default.aspx?queryparsed=id:127681337 |
| Volume | 382 |
| hasFullText | 1 |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| journalDatabaseRights | – providerCode: PRVESC databaseName: Baden-Württemberg Complete Freedom Collection (Elsevier) customDbUrl: eissn: 1474-547X dateEnd: 99991231 omitProxy: true ssIdentifier: ssj0004605 issn: 0140-6736 databaseCode: GBLVA dateStart: 20110101 isFulltext: true titleUrlDefault: https://www.sciencedirect.com providerName: Elsevier – providerCode: PRVESC databaseName: Elsevier SD Complete Freedom Collection [SCCMFC] customDbUrl: eissn: 1474-547X dateEnd: 99991231 omitProxy: true ssIdentifier: ssj0004605 issn: 0140-6736 databaseCode: ACRLP dateStart: 19950107 isFulltext: true titleUrlDefault: https://www.sciencedirect.com providerName: Elsevier – providerCode: PRVLSH databaseName: Elsevier Journals customDbUrl: mediaType: online eissn: 1474-547X dateEnd: 99991231 omitProxy: true ssIdentifier: ssj0004605 issn: 0140-6736 databaseCode: AKRWK dateStart: 19930102 isFulltext: true providerName: Library Specific Holdings – providerCode: PRVPQU databaseName: Health & Medical Collection customDbUrl: eissn: 1474-547X dateEnd: 20250630 omitProxy: true ssIdentifier: ssj0004605 issn: 0140-6736 databaseCode: 7X7 dateStart: 19920104 isFulltext: true titleUrlDefault: https://search.proquest.com/healthcomplete providerName: ProQuest – providerCode: PRVPQU databaseName: ProQuest Central customDbUrl: http://www.proquest.com/pqcentral?accountid=15518 eissn: 1474-547X dateEnd: 20250630 omitProxy: true ssIdentifier: ssj0004605 issn: 0140-6736 databaseCode: BENPR dateStart: 19920104 isFulltext: true titleUrlDefault: https://www.proquest.com/central providerName: ProQuest – providerCode: PRVPQU databaseName: Public Health Database customDbUrl: eissn: 1474-547X dateEnd: 20250630 omitProxy: true ssIdentifier: ssj0004605 issn: 0140-6736 databaseCode: 8C1 dateStart: 19920104 isFulltext: true titleUrlDefault: https://search.proquest.com/publichealth providerName: ProQuest |
| link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwjV3db9MwELfYJiFeEN_LGFWQEAKJsNpO7JgXBNOmCYkJbVTqm-WvToXSbE37_3OXOKlApeOlSuM7JXbu7N_Z90HIK85VCMqKLFCwdPJSBVApxzOrnJPG8TD0jZfvuTgb5V_GxThuuNXRrbKbE5uJ2lcO98iPAPjngFXA6Pl4fZNh1Sg8XY0lNHbIHgWoglItx3JTXGTj4r6O4Dm67G--ofwt5hwHq_pfa9POxFToNGlqGLdJW_BiEyL9K91os0SdPiD3I7ZMP7XC8JDcCfNH5O7XeHr-mPy4mNbBL3C_PKTTedoFcqe4GZtitEd1hVPftE6ngKYX6OlhPqQmhXfx1S9kfpf6amVnIbMAT-Ff49Jlqyx6vM-CT5s6IE_I6PTk-_FZFmstZE4yscyodDJMGEBt7p1hlIPeGjbM8doWxk5sWVifK8BDLJdWOCVsKJzAb20UF_wp2Z1X87BPUiMKbwDIGSl8zuWwnOSwSrpC5p5a5lhC8m6UtYuJyLEexkxv8DijXDcfRw8T8r5nu24zcdzGILpPqLswU5gYNawVtzHKTYyhjupda6prpoctNzJT3rACZ9lzRgTTIpP_eeg-SJk2VzC369Elw50oPFUuJDQN_hC9vvtMlmDtljQhh50s6vU79gqTkJd9M8gKngiZeahWSIP5HMGkldtoBFDJXLGtNBgMBD3ZQoO2P-YXLLbQAHQqihJAeEKetTq17iwgeakoT8jrVsn6FsyQHm_9hKugCyaFUgfbR-U5ucewtAngECYOye5ysQovAGAu7aCZReC3PKYDsvf55PzbxW8wqXI_ |
| linkProvider | ProQuest |
| linkToHtml | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwtV3db9MwELe2IQEviO8FxjASIJAIS2zHTpAQQsDUsY8Htkp9M7bjToXSjKYV4p_ib-QuXxWodLzsLY19TRyf735n3wchjznPvM-sDH0Mlo5IMw9LyvHQZs4p47iP8srL90j2-uLjIBmskV9tLAy6VbYysRLUeeFwj3wHgL8ArAJGz5uz7yFWjcLT1baERs0W-_7nDzDZytd772F-nzC2--HkXS9sqgqETjE5C2PllB8yAJU8d4bFHDjUsEjgtU2MHdo0sbnIQPMzoax0mbQ-cRJHZTIuOfzvOrkkeCQwV78aqGVxmJVL_SJiaOe4u_ks5s8xxzlY8f_ShetDU6CTpilhnoZ1gY1lCPiv9KaVSty9Tq41WJa-rZnvBlnzk5vk8mFzWn-LfPk0Kn0-xf15T0cT2gaOU9z8pRhdUpyiqB2VdATofYqeJeYVNRTeJS--IfELmhdzO_ahBTgMvyoXMluEjYf92Oe0qjtym_QvZBbukI1JMfGbhBqZ5AaAo1EyF1xF6VCAVnaJEnlsmWMBEe1X1q5JfI71N8Z6iYdbzHU1OToKyMuO7KzO_HEegWynULdhrSCINeim8wjVMkJfNuKk1LEumY5qaiSOeUUKlGlH2SCmGgn9z0M3gcu0OQVdovvHDHe-8BQ7UdC0_QfrdcNnKgXrOo0DstXyol68Y7dAA_KoawZewRMoM_HFHPtg_kgwodWqPhJ6KZGxlX0w-AhGsqIP7jVgPsNkRR-AakmSAugPyN16TS0GC5aDymIekKf1IutaMCN7c-srXHmdMCWz7N7qr_KQXOmdHB7og72j_fvkKsOyKoCBmNwiG7Pp3D8AcDuz25VEoeTzRYuw376VrBY |
| linkToPdf | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwtV3db9MwELe2IU28IL4XGMNIgEAitLEdO0FCCDGmjcGEGJX65tmOMxVKM5pWiH-Nv467fFWg0vGytzS-a-L4fP6dfR-EPOQ89T61MvQRWDoiST1MKcdDmzqnjOO-n1VevkdyfyDeDePhGvnVxsKgW2WrEytFnRUO98h7APwFYBUwenp54xbxcXfv1dn3ECtI4UlrW06jFpFD__MHmG_ly4NdGOtHjO29_fxmP2wqDIROMTkLI-WUzxkATJ45wyIO0mpYX-C1jY3NbRLbTKSAAphQVrpUWh87iT00KZcc_nedXFJccHQnU0O1LCazcq9fRA_1jrubTyL-FPOdg0X_r3VxPTcFOmyaEsYsr4ttLEPDf6U6rZbHvavkSoNr6etaEK-RNT-5TjY_NCf3N8iXT6PSZ1Pcq_d0NKFtEDnFjWCKkSbFKardUUlHgOSn6GViXlBD4V2y4hsyP6NZMbdjH1qAxvCrciezRdh42499RqsaJDfJ4EJG4RbZmBQTv0WokXFmAEQaJTPBVT_JBazQLlYiiyxzLCCi_craNUnQsRbHWC_xdou4rgZH9wPyvGM7q7OAnMcg2yHUbYgrKGUN69R5jGoZoy8b1VLqSJdM92tuZI54xQqcScfZoKcaFf3PQ7dAyrQ5hXVFD44Z7oLhiXasoGnnD9Hrus9UApZ2EgVku5VFvXjHbrIG5EHXDLKCp1Fm4os50mAuSTCn1SoaCVRKpGwlDQYiQU9W0OC-A-Y2jFfQAGyL4wQMgIDcrufUorNgRag04gF5XE-yrgWzsze3vsKV1zFTMk3vrP4q98kmKC_9_uDo8C65zLDCCsAhJrfJxmw69_cA587sTqVQKDm5aA32G6BfsFE |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Risedronate+in+children+with+osteogenesis+imperfecta%3A+a+randomised%2C+double-blind%2C+placebo-controlled+trial&rft.jtitle=The+Lancet+%28British+edition%29&rft.au=Bishop%2C+Nick&rft.au=Adami%2C+Silvano&rft.au=Ahmed%2C+S+Faisal&rft.au=Ant%C3%B3n%2C+Jordi&rft.date=2013-10-26&rft.pub=Elsevier+Ltd&rft.issn=0140-6736&rft.eissn=1474-547X&rft.volume=382&rft.issue=9902&rft.spage=1424&rft.epage=1432&rft_id=info:doi/10.1016%2FS0140-6736%2813%2961091-0&rft.externalDocID=US201500130570 |
| thumbnail_m | http://utb.summon.serialssolutions.com/2.0.0/image/custom?url=https%3A%2F%2Fcdn.clinicalkey.com%2Fck-thumbnails%2F01406736%2FS0140673613X60507%2Fcov150h.gif |